Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug ...

Stroke is the fourth leading cause of death among Hispanic men and the third leading cause for Hispanic women in the United States. Yet, according to CDC reports, only 58% of Hispanic adults can ...

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...

Jemperli – the seventh approved drug in the PD-1/PD-L1 inhibitor class – was acquired by GSK as part of its $5.1 billion takeover of Tesaro along with PARP inhibitor Zejula (niraparib ...

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its ...

Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 ...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that ...

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

At that time, the Boston-based firm also added a combination treatment arm in that same Phase I trial, in which patients would receive EO-3021 with either GlaxoSmithKline's PD-1 inhibitor Jemperli ...